MX2020004833A - Un poliepitopo quimerico del virus del zika que comprende proteinas no estructurales y su uso en una composicion inmunogenica. - Google Patents

Un poliepitopo quimerico del virus del zika que comprende proteinas no estructurales y su uso en una composicion inmunogenica.

Info

Publication number
MX2020004833A
MX2020004833A MX2020004833A MX2020004833A MX2020004833A MX 2020004833 A MX2020004833 A MX 2020004833A MX 2020004833 A MX2020004833 A MX 2020004833A MX 2020004833 A MX2020004833 A MX 2020004833A MX 2020004833 A MX2020004833 A MX 2020004833A
Authority
MX
Mexico
Prior art keywords
immunogenic composition
structural proteins
zika virus
polyepitope
zikv
Prior art date
Application number
MX2020004833A
Other languages
English (en)
Inventor
Etienne Simon-Loriere
Claude Roth
Anavaj Sakuntabhai
Felix Delgado
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Publication of MX2020004833A publication Critical patent/MX2020004833A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se dirige a un poliepítopo quimérico del virus de Zika (ZIKV) que comprende proteínas no estructurales y su uso En una composición inmunogénica. La presente invención proporciona medios, en particular polinucleótidos, vectores y células que expresan tal poliepítopo quimérico. La presente invención también se refiere a una composición o una vacuna que comprende al menos uno de tal poliepítopo, polinucleótido, vector o célula hospedera para usar en la prevención de una infección por ZIKV en un sujeto humano, o para usar en la prevención de Infecciones por ZIKV y virus del dengue (DENV) en un sujeto humano.
MX2020004833A 2017-11-09 2018-11-08 Un poliepitopo quimerico del virus del zika que comprende proteinas no estructurales y su uso en una composicion inmunogenica. MX2020004833A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17306553 2017-11-09
PCT/EP2018/080677 WO2019092142A1 (en) 2017-11-09 2018-11-08 A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition

Publications (1)

Publication Number Publication Date
MX2020004833A true MX2020004833A (es) 2021-01-08

Family

ID=60574493

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004833A MX2020004833A (es) 2017-11-09 2018-11-08 Un poliepitopo quimerico del virus del zika que comprende proteinas no estructurales y su uso en una composicion inmunogenica.

Country Status (12)

Country Link
US (2) US11305003B2 (es)
EP (1) EP3707154A1 (es)
JP (1) JP7225254B2 (es)
KR (1) KR20200090186A (es)
CN (1) CN111683959A (es)
AU (1) AU2018365296B2 (es)
BR (1) BR112020009157A2 (es)
CA (1) CA3079776A1 (es)
MX (1) MX2020004833A (es)
PH (1) PH12020550569A1 (es)
SG (1) SG11202004234SA (es)
WO (1) WO2019092142A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11806393B2 (en) * 2017-02-10 2023-11-07 La Jolla Institute For Allergy And Immunology Flavivirus peptide sequences, epitopes, and methods and uses thereof
US11305003B2 (en) 2017-11-09 2022-04-19 Institut Pasteur Zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition
CN113528465B (zh) * 2020-04-20 2023-07-11 中国人民解放军军事科学院军事医学研究院 包含突变的寨卡病毒全基因组cDNA的DNA分子及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60233038D1 (de) 2002-06-20 2009-09-03 Pasteur Institut Infektiöse cDNA eines zugelassenen Impfstammes des Masern Virus. Verwendung in immunogenen Zusammensetzungen
DK1375670T3 (da) 2002-06-20 2013-09-23 Pasteur Institut Rekombinante mæslingevira, der udtrykker epitoper af RNA-viras antigener, samt anvendelse af de rekombinante vira til fremstilling af vaccinesammensætninger
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US8158413B2 (en) 2005-10-17 2012-04-17 Institut Pasteur Lentiviral vector-based vaccine
ES2423518T3 (es) 2006-12-22 2013-09-20 Institut Pasteur Células y metodología para generar virus de ARN de cadena de sentido negativo no segmentada
CN102083462B (zh) 2007-08-03 2015-02-18 巴斯德研究院 慢病毒基因转移载体及其医学应用
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP3384938A1 (en) 2011-09-12 2018-10-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2712871A1 (en) 2012-09-27 2014-04-02 Institut Pasteur Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications
EP3076994A4 (en) 2013-12-06 2017-06-07 Modernatx, Inc. Targeted adaptive vaccines
EP2959915A1 (en) * 2014-06-23 2015-12-30 Institut Pasteur A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection
EP3031923A1 (en) 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
GB201508099D0 (en) * 2015-05-12 2015-06-24 Isis Innovation Dengue vaccines
EP3310382A4 (en) 2015-06-22 2019-01-02 President and Fellows of Harvard College Compositions and methods for modulating viral infection
SG10201913630YA (en) 2016-02-17 2020-03-30 Curevac Ag Zika virus vaccine
WO2017189891A1 (en) * 2016-04-27 2017-11-02 Middle Tennessee State University Methods for treating zika viral infections and associated complications
US10632185B2 (en) * 2016-07-08 2020-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric west nile/zika viruses and methods of use
WO2018009604A1 (en) * 2016-07-08 2018-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric dengue/zika viruses live-attenuated zika virus vaccines
US11666649B2 (en) * 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
US11572390B2 (en) * 2017-03-27 2023-02-07 The University Of Queensland Chimeric insect-specific flaviviruses
US11305003B2 (en) 2017-11-09 2022-04-19 Institut Pasteur Zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition

Also Published As

Publication number Publication date
US20200282043A1 (en) 2020-09-10
JP2021502115A (ja) 2021-01-28
AU2018365296A1 (en) 2020-05-21
US11305003B2 (en) 2022-04-19
KR20200090186A (ko) 2020-07-28
CA3079776A1 (en) 2019-05-16
US20220233678A1 (en) 2022-07-28
BR112020009157A2 (pt) 2020-10-27
JP7225254B2 (ja) 2023-02-20
EP3707154A1 (en) 2020-09-16
SG11202004234SA (en) 2020-06-29
PH12020550569A1 (en) 2021-04-19
CN111683959A (zh) 2020-09-18
AU2018365296B2 (en) 2023-11-23
WO2019092142A1 (en) 2019-05-16
US11872276B2 (en) 2024-01-16

Similar Documents

Publication Publication Date Title
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
CO2018001534A2 (es) Una composicion de vacuna arboviral
MX2020004833A (es) Un poliepitopo quimerico del virus del zika que comprende proteinas no estructurales y su uso en una composicion inmunogenica.
PH12016502554A1 (en) A dengue virus chimeric polyepitope composed of fragments of non structural proteins and its use in an immunogenic composition against dengue virus infection
UY35131A (es) Composiciones, métodos y usos de construcciones de virus del dengue de serotipo-4
AR093578A1 (es) Metodos para la elaboracion de polipeptidos procesados proteoliticamente
CO2018010874A2 (es) Vacuna de virus de zika atenuado vivo
CL2019000640A1 (es) Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y métodos de uso.
AR101814A1 (es) Partícula de tipo virus flavivirus
CL2019000993A1 (es) Meganucleasas diseñadas específicamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b.
AR100606A1 (es) Variantes de lipasas y polinucleótidos que las codifican
CL2015002741A1 (es) Composiciones y métodos para aumentar la respuesta inmune contra patógenos entéricos
MY189334A (en) Lentiviral vector-based japanese encephalitis immunogenic composition
AR094810A1 (es) Parvovirus porcino 5b, métodos de uso y vacuna
PH12017501100B1 (en) Recombinant swinepox virus and vaccines
PE20181087A1 (es) SISTEMA VECTOR DE ADENOVIRUS AVIAR 9 (FAdV-9) Y METODOS ASOCIADOS
CR20170280A (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas
MX2020006476A (es) Vacuna contra el virus de lassa.
PH12020551944A1 (en) Reverse peptide vaccine
BR112016029201A2 (pt) vírus do oeste do nilo/dengue quiméricos e métodos de uso
CL2014000551A1 (es) Célula de levadura con un vector de expresión que comprende un polinucleótido con la secuencia de la proteina de cápside de vp2 del virus de la necrosis pancreática infecciosa (ipnv) y con la secuencia de uno o mas epítopos de la hemaglutinina del virus de la anemia infecciosa del salmón; alimento para peces que comprende la célula de levadura; vacuna oral para peces.
BR112015025420A8 (pt) expressão de inibidores do hiv por células-tronco mesenquimais
AR113488A1 (es) VARIANTES DE a-AMILASA Y POLINUCLEÓTIDOS QUE LAS CODIFICAN
EA202191862A2 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
AR109734A1 (es) Composiciones y métodos de tratamiento de la infección persistente por el virus del papiloma humano (hpv)